Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys
Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys
Source link
Similar Posts
Profit for Colombia’s Grupo Aval jumps six fold in third-quarter By Reuters
(Reuters) – Colombian financial conglomerate Grupo Aval (NYSE:) reported on Wednesday a more than six-fold increase in its third-quarter net profit, climbing to 415.7 billion Colombian pesos ($94.18 million). The firm’s interest income during the July-to-September period, however, fell 6.3% compared to the year-ago period to settle at 6.87 trillion pesos. The company attributed the…
3 Dividend Stocks Raising Payouts—and Backing It Up With Results
Not all dividends are paid out equally; some companies try to create a “trap” by overpaying on a quarter’s dividend, attracting buyers through a short-term high dividend yield that seems too good to pass up. The realization comes much later, though, that these companies can’t afford these payouts, straining the financial profile altogether and having…
Comments on August Employment Report
by Calculated Risk on 9/05/2025 09:11:00 AM The headline jobs number in the August employment report was below expectations and June and July payrolls were revised down by 21,000 combined. A weak report. The participation rate increased, the employment population ratio was unchanged, and the unemployment rate was increased to 4.3%. Prime (25 to 54 Years…
1 Canadian Energy Stocks Poised for Big Growth in 2026
Canadian energy stocks are back in vogue now that oil prices have shot over $100 per barrel. The conflict between Iran and the United States has revealed that the Strait of Hormuz is a major global energy supply lynchpin. Source: Getty Images Canadian energy stocks could enjoy outsized cash flows for some time Not only…
